about
Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndromeValidation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study.Using HitAlert flow cytometry to detect heparin-induced thrombocytopenia antibodies in a tertiary care hospital.Intravenous OxyContin-associated thrombotic microangiopathy treated successfully without plasma exchange.Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome.Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation.Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometryDesign and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.Stem cell transplantation for mantle cell lymphoma: if, when and how?How to diagnose amyloidosis.Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group.Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.Mass spectrometry analysis for amyloidosis typing - is the future bright for its clinical implementation?Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis.Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.Transcriptomic analysis of monocytes and macrophages derived from CLL patients which display differing abilities to respond to therapeutic antibody immune complexes.The duality of macrophage function in chronic lymphocytic leukaemia.Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial.Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis.Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis.Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.Successful treatment of iatrogenic multicentric Castleman's disease arising due to recrudescence of HHV-8 in a liver transplant patient.Malabsorption Secondary to Gout-Induced Amyloidosis.Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis.Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma.Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis.Epstein-Barr virus T-cell immunity despite rituximab.Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.Addition of etoposide to standard acute myeloid leukaemia induction chemotherapy does not improve survival.CD62L as a therapeutic target in chronic lymphocytic leukemia.A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma.A global call to arms for clinical laboratories - Harmonised quantification and reporting of monoclonal proteins.'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.The Utility of 99mTc-DPD Scintigraphy in the Diagnosis of Cardiac Amyloidosis: An Australian Experience.Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.Cardiac Amyloid Imaging with 18F-Florbetaben PET: A Pilot Study.
P50
Q33163717-FEA4DE78-C52C-42B8-922D-96793EDC0FDAQ33399117-A8AE7AF8-ADE3-4B71-A215-997A71E24691Q33406008-8B9579E4-6774-413D-91E4-CD8EC0C3554EQ33421659-6B0BDBD3-BFF0-4231-8296-F3065965B28AQ33439114-8F3BFB41-AB8D-482F-9792-DBA71CFA2C1FQ34212528-48D75086-9E03-4C85-BE4B-2F822D50F02FQ34535087-58544959-99E6-48AA-9147-DD86FED8F598Q36178028-7E434E60-55A9-4570-AB90-05FE575BD27EQ36187791-5C3038A1-7EDE-4BD3-85C6-45DDF9DF8F04Q36188687-4DB0E564-A8F3-446D-BD16-5F7D39AB6E4CQ38136289-969DF965-2375-4CDE-BCE9-256593C4BB0DQ38244397-CF7D4EDB-7A39-4905-9B0B-802C1E19A531Q38316150-8EF47407-7281-4CC8-83DE-61A7E03F6550Q38367249-8390A585-33DF-41FF-B47E-86495B32AB16Q38383351-1EB14A8C-CB0A-4E44-976C-8EFD547FD6CEQ38691489-F47EE97F-F8C9-4B72-BD69-A885CF79689FQ38712280-DD4CCD2B-1DD4-478F-AEB0-A5B9496AC26DQ38749573-1456B0AC-2BAE-4712-BB8D-E13A7A865AE9Q38782911-65EA21CF-41CA-4917-B484-EA7140C09AD4Q39203230-120D23C9-406A-4DB3-A53B-F21B894BA0DDQ40170430-23164DA3-4B04-44B8-BC00-12A2CD3304DCQ40192906-DB485B79-19AD-49FA-A33A-6C1C4C2F435AQ40576636-C885A348-FA1D-401E-93EA-53694C413DB0Q41573231-370FD36F-FE08-49EC-B13E-D439238420E4Q42228667-8796D558-4EBD-491B-AA52-F079DEAF3105Q42317790-E97D6533-33ED-4913-BEBE-98E9B7752B7DQ42628866-275AC749-4B91-4205-A79E-CEC69E2F2A86Q43591861-6D74DB79-1F03-497F-9D26-65131337731DQ44163481-972766CE-41BF-44C4-81A0-AA0D89208267Q44493387-32B94A01-87AD-4607-9666-549070A3059AQ45408294-AC214019-7A46-4CA8-92AC-22C6C4CA683BQ45420586-18B88567-0FFB-4EA8-977F-F90358A533EBQ46095331-88AF2AAF-D326-4252-9DD8-FBA30E47B44FQ46153351-98244B8C-4A30-4A69-B183-A1929A4336FCQ46979566-A26AFC9F-49AA-45B7-9431-A1DD371991DDQ47386065-59ADFEE0-E6BD-4D12-B087-A6828E9094DFQ48205014-0FD0DE39-154F-40E4-BC49-664232DFBE87Q48282896-196712B9-FC8B-43F9-980A-03B1403480E8Q48283228-6B9858A5-1C26-40DF-BBF3-BD222EA6A71DQ48590553-7EE61ADB-0C32-4A8D-8278-29F0972B2B11
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter Mollee
@ast
Peter Mollee
@en
Peter Mollee
@es
Peter Mollee
@nl
type
label
Peter Mollee
@ast
Peter Mollee
@en
Peter Mollee
@es
Peter Mollee
@nl
prefLabel
Peter Mollee
@ast
Peter Mollee
@en
Peter Mollee
@es
Peter Mollee
@nl
P106
P31
P496
0000-0002-8537-1198